FALL 2020 CIHR COMPETITION RESULTS
RI-MUHC teams received $6.9 million in project funding and $2 million more for COVID-19 research
Saliva samples for COVID-19 testing: as good as nasopharyngeal swabs, but cheaper
New meta-analysis of 37 studies and over 7,000 paired saliva and nasopharyngeal swab samples
Could a different testing strategy reduce healthcare workers’ isolation after unprotected exposure to a confirmed case of COVID-19?
RI-MUHC study suggests appropriate...
The RI-MUHC leads new clinical trial of COVID-19 treatment for hospitalized patients
Phase 2 study tests LAU-7b, a Canadian drug with dual antiviral and inflammation-controlling effects
Driving Personalized Medicine: The 2020 RI-MUHC Annual Report is online!
An invitation from Dr. Miguel Burnier Jr.
What do we know about sleep apnea, pregnancy and gestational diabetes?
RI-MUHC researchers find link that may lead to better health for mother and baby
Stem cells are the marrow of the TB pandemic, which still kills one person every 22 seconds
A new study finds that not only can stem cells be targeted for protective vaccination, but they can also ...
Sleep apnea treatment reduces heart problems in patients with prediabetes, a new study finds
People with prediabetes and obstructive sleep apnea could reduce their daytime resting heart rate and risk of cardiovascular disease by using a CPAP machine at night
Nip it in the bud: New study will attack SARS-Cov2 where it multiplies
RI-MUHC researchers initiate a clinical trial of ciclesonide to possibly prevent mild cases of COVID-19 from worsening
RI-MUHC researcher Maziar Divangahi honoured by the Royal Society of Canada
Recognition for high-level achievement in research into pulmonary infectious diseases